Mannuronic Acid in Low‐Risk and Intermediate‐1‐Risk Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Mannuronic Acid in Low‐Risk and Intermediate‐1‐Risk Myelodysplastic Syndromes

Published:2020-02-16 Issue:7 Volume:60 Page:879-888
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Ghaderi Afshin¹,Nodehi Sayyed Reza Safaee¹,Bakhtiari Tahereh²,Aslani Mona²,Aghazadeh Zahra²,Matsuo Hidenori³,Rehm Bernd H. A.⁴,Cuzzocrea Salvatore⁵,Mirshafiey Abbas²⁶

Affiliation:

1. Department of Internal MedicineHematology and Medical Oncology WardCancer Research CentreCancer InstituteImam Khomeini Hospital ComplexTehran University of Medical Sciences Tehran Iran

2. Department of ImmunologySchool of Public HealthTehran University of Medical Sciences Tehran Iran

3. Nagasaki National Hospital Nagasaki Japan

4. Centre for Cell Factories and BiopolymersGriffith Institute for Drug DiscoveryGriffith University Nathan Queensland Australia

5. Department of Chemical, BiologicalPharmaceutical and Environmental SciencesUniversity of Messina Messina Italy

6. Research Centre for ImmunodeficienciesChildren's Medical CentreTehran University of Medical Sciences Tehran Iran

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1587

Reference37 articles.

1. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

2. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS

3. Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes

4. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia